Efficacy and Predictive Factors of Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy
Table 2
Changes in visual acuity and imaging data between the responder group and the nonresponder group.
Baseline
1 month
3 months
6 months
Responder group, 24 eyes
BCVA (logMAR) (decimal equivalent)
0.17 ± 0.28
0.16 ± 0.28
0.09 ± 0.37
0.09 ± 0.21
0.7 ± 0.5
0.7 ± 0.5
0.8 ± 0.4
0.8 ± 0.6
SRF area (mm2)
0.30 ± 0.14
0.13 ± 0.11
0.03 ± 0.05
0
CMT (μm)
339.22 ± 77.75
261.50 ± 56.45
209.00 ± 40.18
189.44 ± 31.42
SFCT (μm)
497.50 ± 99.36
388.50 ± 128.81
362.28 ± 102.02
364.67 ± 102.21
Nonresponder group, 18 eyes
BCVA (logMAR) (decimal equivalent)
0.27 ± 0.27
0.26 ± 0.26
0.17 ± 0.16
0.18 ± 0.30
0.5 ± 0.5
0.5 ± 0.5
0.7 ± 0.7
0.7 ± 0.5
SRF area (mm2)
0.58 ± 0.26†
0.28 ± 0.16†
0.24 ± 0.21†
0.15 ± 0.10†
CMT (μm)
430.86 ± 100.49
328.39 ± 75.09
297.61 ± 108.10
266.21 ± 56.03
SFCT (μm)
365.50 ± 119.04
341.93 ± 111.45
320.43 ± 106.01
329.07 ± 107.09
BCVA, best-corrected visual acuity; SRF, subretinal fluid; CMT, central macular thickness; SFCT, subfoveal choroidal thickness. † compared to the responder group using the Wilcoxon signed-rank sum test. compared to the responder group using an independent sample Student’s t-test.
